BTRC and metabolic dysfunction-associated steatohepatitis: Previous studies introduced PHAR, a protein-protein interaction inhibitor of NRF2/β-TrCP, which impairs β-TrCP-mediated NRF2 degradation selectively activates NRF2 in the liver, and promotes beneficial effects in NASH.